Skip to main content
main-content

Respiratory

Respiratory

20-08-2019 | Oncology | News | Article

Study supports use of fosnetupitant in combination with palonosetron for CINV

A phase II trial shows that the intravenous prodrug fosnetupitant in combination with palonosetron reduces chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

14-08-2019 | Oncology | News | Article

Nivolumab shows long-term clinical efficacy in Japanese patients with advanced NSCLC

Pooled long-term results from two multicenter phase II studies indicate that nivolumab is efficacious in Japanese patients with previously treated, stage IIIB/IV squamous or nonsquamous non-small-cell lung cancer.

01-08-2019 | Respiratory | News | Article

Improved asthma control offers potential for sizeable cost savings

Researchers have projected that the economic burden of uncontrolled asthma in the USA will be in excess of US$ 900 billion over the next 20 years.

24-07-2019 | Oncology | News | Article

HBV reactivation risk ‘moderate to high’ for EGRF–TKI-treated NSCLC

Patients with non-small-cell lung cancer undergoing treatment with an EGFR–tyrosine kinase inhibitor may have a clinically meaningful risk for reactivation of unresolved hepatitis B virus infection during treatment, study findings indicate.

22-07-2019 | Oncology | News | Article

Local ablative therapy–pembrolizumab benefit suggested for metastatic NSCLC

Data from two phase II studies published in JAMA Oncology lend support to the sequential use of local ablative therapy and PD-1 blockade in patients with metastatic non-small-cell lung cancer.

18-07-2019 | Oncology | News | Article

Genomic markers of brain metastasis risk identified in NSCLC

Researchers have identified key genomic alterations in brain metastases matched to primary non-small-cell lung cancer that could serve as prognostic markers and potential therapeutic targets.

12-07-2019 | Oncology | News | Article

Low-dose CT provides superior screening for lung cancer death in high-risk smokers

Findings from an extended follow-up of the National Lung Screening Trial maintain that low-dose computed tomography screening significantly reduces risk for lung cancer death versus chest radiography screening among high-risk current and former smokers.

09-07-2019 | Oncology | News | Article

Vemurafenib monotherapy has potential for BRAF-mutated NSCLC

Single-agent vemurafenib has demonstrated promising antitumor activity against non-small-cell lung cancer harboring BRAF V600E mutations in the VE-BASKET trial.

25-06-2019 | Oncology | News | Article

Pembrolizumab approved in USA for metastatic SCLC

Click through for the details of this FDA decision

24-06-2019 | Oncology | News | Article

Adding chemotherapy to gefitinib improves EGFR-mutated NSCLC outcomes

Supplementing the EGFR–tyrosine kinase inhibitor gefitinib with pemetrexed and carboplatin doubles progression-free survival in patients with advanced, chemotherapy-naïve non-small-cell lung cancer harboring activating EGFR mutations, according to phase III results.

21-06-2019 | Oncology | News | Article

Neoadjuvant immunotherapy shows promise for resectable NSCLC

Neoadjuvant immunotherapy produces encouraging major pathologic response rates among patients with resectable non-small-cell lung cancer, show data presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

20-06-2019 | Oncology | News | Article

Maintenance bevacizumab–pemetrexed improves PFS of nonsquamous NSCLC patients

Two studies presented at the 2019 ASCO Annual Meeting show a significant progression-free survival, but not overall survival, benefit with the addition of pemetrexed to bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer.

18-06-2019 | Rheumatology | News | Article

Nintedanib reduces SSc-ILD progression across various subgroups

Nintedanib slows lung function decline in a variety of patients with systemic sclerosis-associated interstitial lung disease, suggests a subgroup analysis of data from the SENSCIS trial.

14-06-2019 | Rheumatology | News | Article

Safety profile of nintedanib similar in SSc–ILD, IPF

Nintedanib’s safety and tolerability profile is similar in patients with systemic sclerosis-associated interstitial lung disease and those with idiopathic pulmonary fibrosis, according to a comparison of data from the SENSCIS and INPULSIS trials.

14-06-2019 | Oncology | News | Article

TAK-788 shows activity against NSCLC with EGFR exon 20 insertions

The EGFR and HER2 inhibitor TAK-788 has antitumor activity against non-small-cell lung cancer with EGFR exon 20 insertions, according to phase I/II findings reported at the 2019 ASCO Annual Meeting.

14-06-2019 | Rheumatology | News | Article

Pirfenidone disappoints in SSc–ILD trial

Randomized trial findings presented at the EULAR 2019 congress in Madrid, Spain, suggest that pirfenidone does not stabilize or improve lung function in patients with systemic sclerosis-associated interstitial lung disease.

13-06-2019 | Oncology | News | Article

BLU-667 active against RET fusion-positive advanced NSCLC

Phase I data indicate that the selective RET inhibitor BLU-667 elicits durable responses and is well tolerated by individuals with advanced non-small-cell lung cancer harboring a RET fusion.

11-06-2019 | Oncology | News | Article

RELAY: Ramucirumab–erlotinib a potential first-line option for EGFR-mutated NSCLC

Combining erlotinib with ramucirumab significantly improves the progression-free survival of untreated patients with advanced EGFR mutation-positive non-small-cell lung cancer, suggest phase III results presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

07-06-2019 | Oncology | News | Article

Prolonged survival possible with pembrolizumab in advanced NSCLC

Updated results from the phase Ib KEYNOTE-001 trial suggest that some individuals with advanced non-small-cell lung cancer can achieve long-term survival with pembrolizumab monotherapy.

05-06-2019 | Asthma | News | Article

Physicians often underestimate asthma control levels

Researchers have found that physicians often underestimate the level of asthma control in patients.

Image Credits